2012年国际生物制药研发前10名企业盘点

Biopharma's Top R&D Spenders-2012

本文介绍了2012年研发支出在世界排名前10位的制药公司,将汇率因素计算在内,2012年这些公司的总研发费用达703.7亿美元,同比前一年的703.8亿美元有稍有下降。但是大多数公司,比如诺华,默克,强生,葛兰素史克,赛诺菲,礼来,阿斯利康和雅培的研发支出基本持平,只有辉瑞公司的支出大幅下降,而罗氏的一部分支出用在了大规模一次性重组上。AbbVie公司现在已经从雅培公司中拆分出来,形成了一个独立的生物制药企业。

The top-line R＆D spending for the top 10 pharma companies was introduced. Jne gross research budgets for these companies hit S70.37 billion last year, down ever so slightly from S70.38 billion the year before, when viewed at constant exchange rates. But while most companies carefully stayed on an unchanged budget track-Novartis, Merck, J＆J, GlaxoSmithKline, Sanofi, Eli Lilly, AstraZeneca and Abbott-Pfizer registered the big drop in spending that had long ago been forecast. Roche, meanwhile, saw its numbers jump in the face of some big, one-time restructuring costs. And Abbott is making an appearance for the last time as AbbVie has now spun out to forge its own unique path in the biopharma business.